

## DAFTAR PUSTAKA

1. Tessy A, Ardayo, Suwanto. Infeksi saluran kemih dalam Buku Ajar Ilmu Penyakit Dalam. Jilid 3. Edisi 3. Jakarta : Balai Penerbit FKUI; 2001. h .369
2. Achmad IA, dkk. Guidelines Penatalaksanaan Infeksi Saluran Kemih (ISK) dan Genetalia Pria. Jakarta.2007.hal.1
3. Ginting Yosia. Antimicrobial Usage of UTIs in Elderly in Abstracts Book 8<sup>th</sup> JADE 2007. Jakarta : Divisi penyakit tropis dan Infeksi IPD-RSCM ; h.18
4. Gonzalez CM, Schaeffer AJ. Treatment of urinary tract infection: what's old, what's new, and what works. *World J Urol.* 1999;17(6): 372–82
5. Sobel J D, Kaye D. Urinary tract infection in Mandell, douglas and Bennett's. Principles and Practice of Infections Diseases. 6<sup>th</sup> ed. Philadelphia: Elsevier; 2005. p. 881-2
6. Hooton, T. M. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. *Int. J. Antimicrob. Agents.*2003. 22:565–72.
7. Huang, E. S., and R. S. Stafford. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. *Arch. Intern. Med.* 200. 162:41–47.
8. Naber, K. G. Survey on antibiotic usage in the treatment of urinary tract infections. *J. Antimicrob. Chemother.* 2000. 46(Suppl. 1):49–52.
9. Shao HF, Wang WP, Zhang XW, Li ZD. Distribution and resistance trends of pathogens from urinary tract infections and impact on management. *Zhonghua Nan Ke Xue.* 2003;9(9):690–692, 696.
10. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. *J Antimicrob Chemother.* 2003;51(1):69–76.
11. Iqbal J, Rahman M, Kabir MS, Rahman M. Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Bangladesh. *Jpn J Med Sci Biol.* 1997;50(6):241–250.
12. Tolun V, Kucukbasmaci O, Torumkuney-Akbulut D, Catal C, Ang-Kucuker M, Ang O. Relationship between ciprofloxacin resistance and

- extended-spectrum beta-lactamase production in *Escherichia coli* and *Klebsiella pneumoniae* strains. *Clin Microbiol Infect.* 2004;10(1):72–75.
13. Hooper DC. Emerging Mechanism of Fluoroquinolone Resistance. *Emerging Infectious Disease.* Vol. 7, No. 2, March-April 2001
  14. Sukandar E. Infeksi saluran kemih pada pasien dewasa dalam Buku Ajar Ilmu Penyakit Dalam. Jilid I. Edisi IV. Jakarta : Balai Penerbit FKUI; 2007. h.553-7
  15. Mims et al. *Medical microbiology.* 2<sup>nd</sup> ed. London: Mosby; 2005. p. 25-7, 411-9
  16. Brooks GF, Butel JS, Morse SA. Jawetz, melnick, & adelberg's medical microbiology. 23<sup>rd</sup> ed. New York:Lange medical books;2004. p. 15-31, 184-6
  17. Boel T. infeksi Saluran Kemih. Diunduh dari *USU digital library.* 2004
  18. Crumplin, G. C., M. Kenwright, and T. Hirst. Investigations into the mechanisms of action of the antibacterial agent norfloxacin. *J. Antimicrob. Chemother.* 1984. 13(Suppl. B):9-23.
  19. Ryan K J, editor. *Sherris medical microbiology.* New York: Prentice-Hall International Inc.; 1998
  20. Setiabudi Rianto. Pengantar Antimikroba dalam Farmakologi dan Terapi. Edisi 7. Jakarta: Gaya Baru; 2007. h. 596
  21. Setiabudy R. Golongan kuinolon dan fluorokuinolon. Dalam Farmakologi dan Terapi. Edisi 7. Jakarta: Gaya Baru; 2007. h. 718-719
  22. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. *J Antimicrob Chemother.* 2001;48(1):37–45.
  23. Kamberi M, Tsutsumi K, Kotegawa T, et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. *Antimicrob Agents Chemother.* 1999;43(3):525–529.
  24. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. *Am Fam Physician.* 2000;61(9):2741–2748.
  25. Jacoby, G. A. Mechanisms of resistance to quinolones. *Clin. Infect. Dis.* 2005. 41(Suppl. 2):S120–S126.

26. Nordmann, P., and L. Poirel. Emergence of plasmid-mediated resistance to quinolones in *Enterobacteriaceae*. *J. Antimicrob. Chemother.* 2005;56: 463-9.
27. Robicsek, A., J. Strahilevitz, G. A. Jacoby, M. Macielag, D. Abbanat, C. H. Park, K. Bush, and D. C. Hooper. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat. Med.* 12:83–88.
28. Samirah, dkk.. Pola dan Sensitivitas Kuman di Penderita Infeksi Saluran Kemih dalam *Indonesian Journal of Clinical Pathology and Medical Laboratory*, Vol. 12, No. 3, Juli 2006: 110-113
29. Navaneeth BV, Belwadi S, Suganthi N. Urinary pathogens' resistance to common antibiotics: a retrospective analysis. *Trop Doct.* 2002;32(1):20–22.
30. Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). *Diagn Microbiol Infect Dis.* 2001;40(3):129–136.
31. Farooqi BJ, Shareeq F, Rizvi QK, Qureshi HS, Ashfaq MK. Changing pattern of antimicrobial susceptibility of organisms causing community acquired urinary tract infections. *J Pak Med Assoc.* 2000;50(11):369–373.
32. Astal ZE. Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. *J of Biomed an Biotech.* 2005;2005(3):238-41.
33. Refdanita, Maksum R, Nurgani A, Endang. Pola kepekaan kuman terhadap antibiotika di ruang rawat intensif Rumah Sakit Fatmawati Jakarta tahun 2001 – 2002. *Makara, kesehatan* 2004;8(2):41-8.
34. Diekema, D. J., B. J. BootsMiller, T. E. Vaugh, R. F. Woolson, J. W. Yankey, E. J. Ernst, S. D. Flach, M. M. Ward, C. L. J. Franciscus, M. A. Pfaller, and B. N. Doebbeling. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. *Clin. Infect. Dis.* 38:78–85.
35. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among Gram negative bacilli in US intensive care units. *JAMA* 289:885–888.

36. Viray, M., D. Linkin, J. N. Maslow, D. D. Stieritz, L. S. Carson, W. B. Bilker, and E. Lautenbach. Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. *Infect. Cont. Hosp. Epidemiol.* 2005. 26:56–62.
37. Zhanel, G. G., T. L. Hisanaga, N. M. Laing, et al, and the NAUTICA Group. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int. J. Antimicrob. Agents.* 2005. 26:380–388.
38. Goettsch, W., W. van Pelt, N. Nagelkerke, M. et al. Increasing resistance to fluoroquinolones in *Escherichia coli* from urinary tract infections in The Netherlands. *J. Antimicrob. Chemother.* 2000. 46:223–228.
39. Alos JI, Serrano MG, Gomez-Garces JL, Perianes J: Antibiotic resistance of *Escherichia coli* from community acquired urinary tract infections in relation to demographic and clinical data. *Clin Microbiol Infect.* 2005, 11:199-203.
40. Hames L, Rice CE: Antimicrobial Resistance of Urinary Tract Isolates in acute uncomplicated cystitis among college aged women: Choosing a first line therapy. *J Am Coll Health* 2007, 56:153-156.
- 41.